North American Scientific To Host Fiscal First Quarter 2008 Financial Results Conference Call on Wednesday, March 19, 2008
March 12, 2008
Chatsworth, CA – March 12, 2008 — North American Scientific, Inc. (Nasdaq: NASI) announced today that it will issue financial results for the first fiscal quarter of 2008, which ended January 31, 2008, at market close on Wednesday, March 19, 2008. The Company will host an investor conference call to review its first quarter 2008 financial results and latest corporate developments, beginning at 1:30 p.m. Pacific Time/4:30 p.m. Eastern Time on Wednesday, March 19, 2008. The dial-in number for the conference call is 800-798-2801 for domestic participants and 617-614-6205 for international participants.
A live webcast of North American Scientific's conference call will be available over the Internet through its website at www.nasmedical.com in the Investor Center. For those who cannot listen to the live webcast, a taped replay of the call will be available beginning approximately one hour after the call’s conclusion and will remain available for seven days. It can be accessed at the same site shortly after the call, or by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers, using the passcode 79158387.
About North American Scientific
North American Scientific is a leader in radiation therapy in the fight against cancer. Its innovative products provide physicians with tools for the treatment of various types of cancers. They include Prospera® brachytherapy seeds and SurTRAK™ needles and strands used primarily in the treatment of prostate cancer. In addition, the Company has been gaining clinical experience with its first generation ClearPath™ multi-channel catheter breast brachytherapy devices in 2007, and intends to launch the second generation devices in 2008. They are the only such devices approved for both high dose and continuous release, or low dose, radiation treatments. The devices are designed to provide flexible, precise dose conformance and an innovative delivery system that is intended to offer the more advanced form of brachytherapy for the treatment of breast cancer. Please visit www.nasmedical.com for more information.
Company:
John Rush, CEO
IR@nasmedical.com
(818) 734-8600
|
|
|
Email a question to our Investor Relations department |
 |
Click to download Windows Media Player. |
 |
Click to download RealPlayer. |
In connection with the following webcast, the Company wishes to take advantage of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 with respect to statements that may be deemed to be forward-looking statements under the Act. Such forward looking statements could include general or specific comments by Company officials about future Company performance, as well as certain responses to questions posed to Company officials about future operating matters. The Company wishes to caution listeners of this call that numerous factors could cause actual results to differ materially from any forward-looking statements made by the Company. These factors include the risk factors set forth in the Company's SEC filings, including its report on Form 10-KSB for the fiscal year ended October 31, 1998, as well as certain factors identified from time to time in the Company's periodic reports filed with the SEC. Any forward-looking statements made in this call speak only as of the date of this call, and the Company undertakes no obligation to revise or update any forward-looking statements, whether as a result of new information, future results, or otherwise.
